ImPact Biotech Receives FDA Clearance for Padeliporfin VTP Phase I Clinical Program in Peripheral Lung Cancer

The planned Phase I/Ib, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects, is designed as a multicenter, open-label study of Padeliporfin Vascular Targeted Photodynamic using Robotic Assisted Bronchoscopy and cone beam CT guidance for lung tumor ablation in patients with Peripheral Lung Cancer.